Tracleer Bosentan Antitrust Settlement $65 Million Over Pay-for-Delay Claims

Tracleer (bosentan) is a prescription drug used for certain serious conditions, and it sits within a tightly regulated pharmaceutical marketplace where manufacturers, pharmacy benefit managers (PBMs), and insurers negotiate prices and coverage. In this class action, a group of third-party payors—entities that purchase or reimburse health care on behalf of others, such as insurers and health plans—alleged that Actelion and related parties used “pay-for-delay” tactics to keep cheaper generic versions of bosentan off the market for longer than they otherwise would have been. These claims arise from a long-running antitrust concern: agreements between brand-name drug makers and generic competitors that can unlawfully trade money for delayed entry can harm consumers, insurers, and the health system by raising or prolonging higher drug costs. The lawsuit was filed to recover damages and obtain a settlement tied to those alleged overcharges, and its significance lies in the size of the resolution—$65 million—while still reflecting the common structure of these cases: the defendants deny wrongdoing, and the court does not decide the merits as part of the settlement. Settlements like this matter because they provide a concrete source of compensation for payors that argue they were forced to pay more, and they also reinforce incentives for compliance in patent and settlement negotiations. More broadly, pay-for-delay antitrust litigation has been a recurring theme in U.S. federal courts, including cases where insurers and other payors sue under federal antitrust laws and where investigators scrutinize agreements that may reduce competition after patent disputes. Industry-wise, the case sits at the intersection of drug patent practice and competition enforcement. The pharmaceutical patent system allows challenges and market entry pathways, but antitrust regulators and courts have repeatedly treated certain settlement payments between brand and generic firms as potentially anticompetitive, especially when they appear intended to delay generic competition rather than resolve disputes through legitimate licensing or early entry. Similar actions have followed the same general theory, focusing on how market exclusivity can translate into higher prices when generics are kept out, and how those effects ripple through health plan formularies and reimbursement decisions.